Fagron NV
F:4A5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fagron NV
F:4A5
|
BE |
|
Sonae SGPS SA
F:YSON
|
PT |
|
D
|
Deutsche Telekom AG
XHAM:DTE
|
DE |
|
C
|
Constellation Software Inc
XBER:W9C
|
CA |
Fagron NV
Fagron NV is a pharmaceutical company focused on compounding, which means making customized medicines for patients whose needs are not met by standard mass-market drugs. It sells raw materials, ready-to-use ingredients, compounding equipment, and prepared formulations that pharmacies, hospital pharmacies, and compounding centers use to make those medicines. Its customers are mainly pharmacists, hospitals, clinics, and other healthcare providers that need reliable supply and technical support for sterile and non-sterile preparations. Fagron makes money by selling products and consumables, plus higher-value services such as formulation support, training, and specialized compounding solutions. What makes Fagron different is its role as a specialist supplier to the compounding part of the healthcare system. Instead of selling directly to patients, it sits in the middle of the medicine-making chain, helping pharmacists prepare customized treatments safely and consistently.
Fagron NV is a pharmaceutical company focused on compounding, which means making customized medicines for patients whose needs are not met by standard mass-market drugs. It sells raw materials, ready-to-use ingredients, compounding equipment, and prepared formulations that pharmacies, hospital pharmacies, and compounding centers use to make those medicines.
Its customers are mainly pharmacists, hospitals, clinics, and other healthcare providers that need reliable supply and technical support for sterile and non-sterile preparations. Fagron makes money by selling products and consumables, plus higher-value services such as formulation support, training, and specialized compounding solutions.
What makes Fagron different is its role as a specialist supplier to the compounding part of the healthcare system. Instead of selling directly to patients, it sits in the middle of the medicine-making chain, helping pharmacists prepare customized treatments safely and consistently.
Strong Organic Growth: Fagron delivered 12.8% organic revenue growth at constant exchange rates and total revenue of EUR 429 million for H1 2024.
Margin Expansion: EBITDA margin increased by 30 basis points to 19.7%, reflecting operational efficiency and acquisition synergies.
Upgraded Guidance: Full-year 2024 revenue guidance was raised to EUR 850–870 million, with continued margin improvement expected.
Regional Drivers: North America led growth with 26.2% revenue increase, LATAM and EMEA also contributed positively despite headwinds in Poland.
Significant Investments: Announced EUR 50 million investment in the Netherlands and $39 million in Wichita, US, to expand capacity and automation.
Drug Shortage Impact: Anazao benefited from US drug shortages, contributing $12 million in revenue in H1, with a similar amount expected in H2.
Strong Cash Flow: Operating cash flow grew by 35% (adjusted for factoring), with net debt/EBITDA at 1.5x, leaving headroom for further M&A.
